Adma Biologics Inc
ADMA
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
21% downsideOvervalued by 21% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.03 Billion |
|---|---|
| Enterprise Value | $2.10 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.62 |
| Beta | 0.73 |
| Outstanding Shares | 236,072,751 |
Return
| Return on Equity | 42.36% |
|---|---|
| Return on Assets | 24.86% |
| Return on Invested Capital | 36.24% |
Valuation & Multiples
| P/E Ratio | 12.68 |
|---|---|
| PEG | 18.52 |
| Price to Sales | 4.48 |
| Price to Book Ratio | 8.95 |
| Enterprise Value to Revenue | 4.11 |
| Enterprise Value to EBIT | 9.77 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.53 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3477▼ 27.31% |
|---|---|
| Total Calls | 6,445,900▲ 119.76% |
| Total Puts | 2,241,200▲ 23.08% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 88.89%▼ 3.46% |
|---|---|
| Total Invested | $1.91B▼ 52.40% |
| Investors Holding | 3720% |
ESG Score
No data
About Adma Biologics Inc
Relevant Senate Committees
Control over Medicare and Medicaid reimbursement policy is the most significant driver of pricing and market access for ADMA's specialty biologics.
This committee determines the specific funding levels for the FDA and other health agencies, directly impacting the speed and resources available for regulatory oversight.
This committee directly oversees the FDA, which regulates the approval and manufacturing processes for all of ADMA's plasma-derived products.
Oversight of patent law and antitrust enforcement is critical for protecting the intellectual property of biologics and regulating market competition.
The committee's focus on drug pricing and chronic disease management creates significant headline risk and legislative pressure for manufacturers of immune-related therapies.